Pulmonary HypertensionNCT07082400
Screening and Phenotyping of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction .
A study testing right heart catheter in people with Pulmonary Hypertension, run by Sohag University.
Trial summary
Left-sided heart failure (HF) is known to cause pulmonary hypertension (PH), but the development and severity of PH in HF is highly variable, and contributing factors are not fully understood. Pulmonary hypertension (PH) due to left heart disease (PH-LHD) is a growing health problem with high morbidity and mortality . Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pulmonary Hypertension
- What is being tested?
- right heart catheter
- Type of treatment
- Surgery or procedure
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 1 Aug 2025to 1 Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All patients diagnosed with diastolic heart failure through The H2FPEF score and suspected pulmonary hypertension
Who cannot join
- Heart Failure with reduced ejection fraction .
- Severe lung diseases as a comborbid condition ,such as COPD (GOLD) class 4 , severe interstitial lung disease.
- Chronic thromboembolic PH .
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Hamdy M Radwan, Professor contact
About this study
Left-sided heart failure (HF) is known to cause pulmonary hypertension (PH), but the development and severity of PH in HF is highly variable, and contributing factors are not fully understood. Pulmonary hypertension (PH) due to left heart disease (PH-LHD) is a growing health problem with high morbidity and mortality . PH-LHD is the most frequent subset of PH, resulting from left ventricular (LV) dysfunction (systolic and/or diastolic) and/or valvular heart disease (VHD) . Although initial studies focused on patients with reduced left ventricular ejection fraction (EF) , early isolated case reports and more recent case series have shown that PH can occur in heart failure with preserved ejection fraction (HFpEF). There is now growing appreciation that PH is common and may be severe in elderly patients with HFpEF . However, the true prevalence and severity of PH in HFpEF from the general community remain unknown. Previous studies were limited by selection bias, and population-based data have, to date, been lacking. Common to left ventricular failure regardless of EF, increased left-sided filling pressure leads to pulmonary venous hypertension (HTN) and post-capillary PH. In the presence of preserved systolic function, the development of pulmonary venous HTN is associated with the severity of left ventricular diastolic dysfunction, as has been shown in patients with aortic stenosis and normal EF. Beyond this post-capillary contribution to PH, a reactive increase in pulmonary arterial tone or intrinsic arterial remodeling can result in a superimposed pre-capillary component of pulmonary arterial HTN. This has been shown to occur in patients with mitral stenosis and HF with reduced EF. In HFpEF without valvular disease, however, the relative contributions of these pre- and post-capillary components to PH are unclear. Pulmonary arterial compliance (CPA) is a predictor of prognosis in patients with SHF, irrespective of pulmonary vascular resistance (PVR).Recently, at the fifth World Symposium on Pulmonary Hypertension in Nice, France, in 2013, two subsets of PH-LHD (post-capillary PH) were defined as isolated post-capillary PH (Ipc-PH; diastolic pulmonary vascular pressure gradient [DPG] < 7 mm Hg, previously labeled as "passive" PH-LHD) and combined pre- and post-capillary PH (Cpc-PH; DPG ≥ 7 mm Hg, previously labeled as "out-of-proportion" or "reactive" PH-LHD, because of pulmonary pressures higher than expected from increased pulmonary artery wedge pressure (PAWP). HF therapies such as β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and spironolactone improve LV function and reduce LV filling pressures, but have not been convincingly shown to improve RV function in humans. In contrast, pulmonary vasodilators that have been approved for the treatment of pulmonary arterial hypertension (PAH) have never demonstrated a benefit in HF populations, including recent randomized trials . There are Diagnostic Dilemmas as diastolic heart failure causing pulmonary hypertension and pulmonary hypertension causing diastolic dysfunction. Chronic right ventricular pressure overload can affect left ventricular diastolic function in several ways. Left ventricular relaxation is under the triple control of load, myocardial properties, and the uniformity of load in space and time .18 In chronic right ventricular pressure overload, the load on the intraventricular septum is dramatically increased and as it hypertrophies, the myocardial properties of the septum are altered. The motion of the intraventricular septum in systole and diastole is asynchronous. All these factors could contribute to impairment in global left ventricular relaxation. In Doppler echocardiographic studies of IPAH, impaired relaxation with decreased E/A ratio and increased isovolumic relaxation time and deceleration time have been consistently reported . While patients must have normal PCWP to be diagnosed with IPAH, there is considerable evidence that chronic right ventricular pressure overload can cause reduced left ventricular compliance. The external forces affecting the LV-EDPVR include right ventricular pressure and pericardial pressure.19_20 The effect of right ventricular pressures on the LV-EDPVR is termed "ventricular interdependence" and is accentuated in the presence of an intact pericardium . These effects were also apparent in chronic right ventricular pressure overload, but a decrease in myocardial compliance (as assessed by the stress-strain relationship) was also seen.
- Conditions
- Pulmonary Hypertension
- Being tested
- right heart catheter
- Medical subject headings
- Hypertension, Pulmonary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
right heart catheterProcedure or surgery
measurement of hemodynamics of pulmonary circulation in patients diagnosed with heart failure with preserved ejection fraction
What is being measured
The primary outcome is the main question the study is designed to answer.
mean pulmonary arterial pressure
through right heart catheter
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2025
- Study start1 Aug 2025 (estimated)
- Primary completion1 Aug 2026 (estimated)
- Study completion1 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Pulmonary HypertensionStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Mohamed Sayed, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07082400
- Sponsor's protocol ID
- Soh-Med-25-6--3MD
- Status last verified
- Jul 2025
- First submitted
- 16 Jul 2025
- Last updated
- 24 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Maron BA, Bortman G, De Marco T, Huston JH, Lang IM, Rosenkranz SH, Vachiery JL, Tedford RJ. Pulmonary hypertension associated with left heart disease. Eur Respir J. 2024 Oct 31;64(4):2401344. doi: 10.1183/13993003.01344-2024. Print 2024 Oct.
PubMed 39209478Wissmuller M, Dohr J, Adler J, Ochs L, Tichelbacker T, Hohmann C, Baldus S, Rosenkranz S. Pulmonary hypertension associated with left heart disease. Herz. 2023 Aug;48(4):266-273. doi: 10.1007/s00059-023-05189-z. Epub 2023 Jun 8.
PubMed 37289211Madonna R, Biondi F, Ghelardoni S, D'Alleva A, Quarta S, Massaro M. Pulmonary hypertension associated to left heart disease: Phenotypes and treatment. Eur J Intern Med. 2024 Nov;129:1-15. doi: 10.1016/j.ejim.2024.07.030. Epub 2024 Aug 1.
PubMed 39095300Redfield MM, Borlaug BA. Heart Failure With Preserved Ejection Fraction: A Review. JAMA. 2023 Mar 14;329(10):827-838. doi: 10.1001/jama.2023.2020.
PubMed 36917048
Study at a glance
From the registry record, last updated by the sponsor on 24 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Screening and Phenotyping of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction .
- ClinicalTrials.gov ID
- NCT07082400
- Acronym / sponsor ID
- Soh-Med-25-6--3MD
- Conditions
- Pulmonary Hypertension
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Aug 2025 (estimated)
- Primary completion
- 1 Aug 2026 (estimated)
- Study completion
- 1 Aug 2026 (estimated)
- First posted
- 24 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Left-sided heart failure (HF) is known to cause pulmonary hypertension (PH), but the development and severity of PH in HF is highly variable, and contributing factors are not fully understood. Pulmonary hypertension (PH) due to left heart disease (PH-LHD) is a growing health problem with high morbidity and mortality . PH-LHD is the most frequent subset of PH, resulting from left ventricular (LV) dysfunction (systolic and/or diastolic) and/or valvular heart disease (VHD) . Although initial studies focused on patients with reduced left ventricular ejection fraction (EF) , early isolated case reports and more recent case series have shown that PH can occur in heart failure with preserved ejection fraction (HFpEF). There is now growing appreciation that PH is common and may be severe in elderly patients with HFpEF . However, the true prevalence and severity of PH in HFpEF from the general community remain unknown. Previous studies were limited by selection bias, and population-based data have, to date, been lacking. Common to left ventricular failure regardless of EF, increased left-sided filling pressure leads to pulmonary venous hypertension (HTN) and post-capillary PH. In the presence of preserved systolic function, the development of pulmonary venous HTN is associated with the severity of left ventricular diastolic dysfunction, as has been shown in patients with aortic stenosis and normal EF. Beyond this post-capillary contribution to PH, a reactive increase in pulmonary arterial tone or intrinsic arterial remodeling can result in a superimposed pre-capillary component of pulmonary arterial HTN. This has been shown to occur in patients with mitral stenosis and HF with reduced EF. In HFpEF without valvular disease, however, the relative contributions of these pre- and post-capillary components to PH are unclear. Pulmonary arterial compliance (CPA) is a predictor of prognosis in patients with SHF, irrespective of pulmonary vascular resistance (PVR).Recently, at the fifth World Symposium on Pulmonary Hypertension in Nice, France, in 2013, two subsets of PH-LHD (post-capillary PH) were defined as isolated post-capillary PH (Ipc-PH; diastolic pulmonary vascular pressure gradient [DPG] < 7 mm Hg, previously labeled as "passive" PH-LHD) and combined pre- and post-capillary PH (Cpc-PH; DPG ≥ 7 mm Hg, previously labeled as "out-of-proportion" or "reactive" PH-LHD, because of pulmonary pressures higher than expected from increased pulmonary artery wedge pressure (PAWP). HF therapies such as β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and spironolactone improve LV function and reduce LV filling pressures, but have not been convincingly shown to improve RV function in humans. In contrast, pulmonary vasodilators that have been approved for the treatment of pulmonary arterial hypertension (PAH) have never demonstrated a benefit in HF populations, including recent randomized trials . There are Diagnostic Dilemmas as diastolic heart failure causing pulmonary hypertension and pulmonary hypertension causing diastolic dysfunction. Chronic right ventricular pressure overload can affect left ventricular diastolic function in several ways. Left ventricular relaxation is under the triple control of load, myocardial properties, and the uniformity of load in space and time .18 In chronic right ventricular pressure overload, the load on the intraventricular septum is dramatically increased and as it hypertrophies, the myocardial properties of the septum are altered. The motion of the intraventricular septum in systole and diastole is asynchronous. All these factors could contribute to impairment in global left ventricular relaxation. In Doppler echocardiographic studies of IPAH, impaired relaxation with decreased E/A ratio and increased isovolumic relaxation time and deceleration time have been consistently reported . While patients must have normal PCWP to be diagnosed with IPAH, there is considerable evidence that chronic right ventricular pressure overload can cause reduced left ventricular compliance. The external forces affecting the LV-EDPVR include right ventricular pressure and pericardial pressure.19_20 The effect of right ventricular pressures on the LV-EDPVR is termed "ventricular interdependence" and is accentuated in the presence of an intact pericardium . These effects were also apparent in chronic right ventricular pressure overload, but a decrease in myocardial compliance (as assessed by the stress-strain relationship) was also seen.
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- All patients diagnosed with diastolic heart failure through The H2FPEF score and suspected pulmonary hypertension
Key exclusion criteria (3 listed)
- Heart Failure with reduced ejection fraction .
- Severe lung diseases as a comborbid condition ,such as COPD (GOLD) class 4 , severe interstitial lung disease.
- Chronic thromboembolic PH .
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| right heart cathetermeasurement of hemodynamics of pulmonary circulation in patients diagnosed with heart failure with preserved ejection fraction | Procedure or surgery | – |
Primary outcome
mean pulmonary arterial pressure
Time frame: 1 year
through right heart catheter
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jul 2025.
- Background: PubMed 39209478Maron BA, Bortman G, De Marco T, Huston JH, Lang IM, Rosenkranz SH, Vachiery JL, Tedford RJ. Pulmonary hypertension associated with left heart disease. Eur Respir J. 2024 Oct 31;64(4):2401344. doi: 10.1183/13993003.01344-2024. Print 2024 Oct.
- Background: PubMed 37289211Wissmuller M, Dohr J, Adler J, Ochs L, Tichelbacker T, Hohmann C, Baldus S, Rosenkranz S. Pulmonary hypertension associated with left heart disease. Herz. 2023 Aug;48(4):266-273. doi: 10.1007/s00059-023-05189-z. Epub 2023 Jun 8.
- Background: PubMed 39095300Madonna R, Biondi F, Ghelardoni S, D'Alleva A, Quarta S, Massaro M. Pulmonary hypertension associated to left heart disease: Phenotypes and treatment. Eur J Intern Med. 2024 Nov;129:1-15. doi: 10.1016/j.ejim.2024.07.030. Epub 2024 Aug 1.
- Background: PubMed 36917048Redfield MM, Borlaug BA. Heart Failure With Preserved Ejection Fraction: A Review. JAMA. 2023 Mar 14;329(10):827-838. doi: 10.1001/jama.2023.2020.
- Individual participant dataSharing planned: Undecided
Related trials for Pulmonary Hypertension
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Active, not recruitingPhase 1
A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)
Pulmonary Arterial Hypertension
RecruitingObservational study
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Pulmonary Disease, Pulmonary Hypertension
Active, not recruitingPhase 1
Study of Intravenous ZMA001 in Healthy Subjects
Pulmonary Arterial Hypertension PAH
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hamdy M Radwan, Professor contact
Questions about this trial
What is this clinical trial studying?
A study testing right heart catheter in people with Pulmonary Hypertension, run by Sohag University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 24 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ahmed M Sayed, Assistant lecturer (+201095630589, ahmed_mahmoud4@med.sohag.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
mean pulmonary arterial pressure (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07082400, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2025.